Hypoxia News and Research RSS Feed - Hypoxia News and Research

Hypoxia is a condition in which there is a decrease in the oxygen supply to a tissue. In cancer treatment, the level of hypoxia in a tumor may help predict the response of the tumor to the treatment.
UT Southwestern researchers find that acetate speeds up growth and metastasis of tumors

UT Southwestern researchers find that acetate speeds up growth and metastasis of tumors

UT Southwestern Medical Center researchers seeking novel ways to combat cancer found that giving acetate, a major compound produced in the gut by host bacteria, to mice sped up the growth and metastasis of tumors. [More]
New findings could pave way to develop drug therapies for necrosis-related diseases

New findings could pave way to develop drug therapies for necrosis-related diseases

Strokes, heart attacks and traumatic brain injuries are separate diseases with certain shared pathologies that achieve a common end - cell death and human injury due to hypoxia, or lack of oxygen. [More]
23andMe announces publication of genome-wide association study of motion sickness

23andMe announces publication of genome-wide association study of motion sickness

23andMe, Inc., the leading personal genetics company, today announced the publication of the first ever genome-wide association study of motion sickness. [More]
Mathematical models of cancer behavior offer new insights on tumor growth

Mathematical models of cancer behavior offer new insights on tumor growth

Hassan Fathallah-Shaykh, M.D., Ph.D., believes that math can transform medicine, and he has the numbers to prove it. [More]
Lilly receives FDA approval for CYRAMZA (ramucirumab)

Lilly receives FDA approval for CYRAMZA (ramucirumab)

Eli Lilly and Company has received its third U.S. Food and Drug Administration approval for CYRAMZA (ramucirumab). [More]
Johns Hopkins researchers discover new way to treat triple-negative breast cancer

Johns Hopkins researchers discover new way to treat triple-negative breast cancer

Triple-negative breast cancer is as bad as it sounds. The cells that form these tumors lack three proteins that would make the cancer respond to powerful, customized treatments. Instead, doctors are left with treating these patients with traditional chemotherapy drugs that only show long-term effectiveness in 20 percent of women with triple-negative breast cancer. [More]
Pembrolizumab shows promising results in patients with classical Hodgkin Lymphoma

Pembrolizumab shows promising results in patients with classical Hodgkin Lymphoma

Merck, known as MSD outside of Canada and the United States, announced today early study findings demonstrating that patients treated with pembrolizumab, the company's investigational anti-PD-1 cancer therapy, achieved an overall response rate of 66 percent, as assessed by International Harmonization Project response criteria (n=19/29: 95% CI, 46-82). [More]
VE-PTP potential treatment target for retinal and choroidal vascular diseases

VE-PTP potential treatment target for retinal and choroidal vascular diseases

Targeting vascular endothelial-protein tyrosine phosphatase, which negatively regulates TIE2 activation, could help to stabilise retinal and choroidal blood vessels, researchers report. [More]
Researchers reveal how cancer cells succeed at entrapping genetic program of growth inhibition

Researchers reveal how cancer cells succeed at entrapping genetic program of growth inhibition

Healthy cells reduce their growth when there is a lack of oxygen (hypoxia). This makes it even more surprising that hypoxia is a characteristic feature of malignant tumours. In two publications in the current edition of the "Nature Communications" journal, researchers from Goethe University and Justus-Liebig-University of Giessen report on how cancer cells succeed at circumventing the genetic program of growth inhibition. [More]
Research breakthrough offers hope for patients with severe spinal cord injuries

Research breakthrough offers hope for patients with severe spinal cord injuries

Case Western Reserve researchers have developed a procedure that restores function to muscles involved in the control of breathing - even when they have been paralyzed for more than a year. The breakthrough offers hope that one day patients with severe spinal cord injuries will be able to breathe again without the assistance of a ventilator. [More]
Researchers develop genetic test to predict prostate cancer recurrence

Researchers develop genetic test to predict prostate cancer recurrence

Prostate cancer researchers have developed a genetic test to identify which men are at highest risk for their prostate cancer to come back after localized treatment with surgery or radiotherapy. [More]
AZD3965 drug inhibits growth of tumours in the lab

AZD3965 drug inhibits growth of tumours in the lab

Manchester scientists have shown that a new drug inhibits the growth of tumours in the lab and that its effectiveness is improved by combining it with radiotherapy - suggesting a new approach that could be used in the clinic. [More]
FDA approves CYRAMZA in combination with paclitaxel for advanced adenocarcinoma

FDA approves CYRAMZA in combination with paclitaxel for advanced adenocarcinoma

Eli Lilly and Company announced today that the U.S. Food and Drug Administration (FDA) has approved CYRAMZA (ramucirumab) in combination with paclitaxel (a type of chemotherapy) as a treatment for people with advanced or metastatic gastric (stomach) or gastroesophageal junction (GEJ) adenocarcinoma whose cancer has progressed on or after prior fluoropyrimidine- or platinum-containing chemotherapy. [More]
GlassesOff mobile app improves visual acuity, image processing speed in IAF pilots

GlassesOff mobile app improves visual acuity, image processing speed in IAF pilots

GlassesOff Inc. (OTCBB: GLSO) today announced that statistically significant interim results from a study commissioned by the Israeli Air Force (IAF) demonstrated significant improvements in critical visual functions of IAF pilots through the use of the GlassesOff mobile app. [More]

CTRC researcher receives special $1.62 million orphan disease grant from FDA

A researcher at the Cancer Therapy & Research Center is the leader on a study receiving a special $1.62 million orphan disease grant from the Food & Drug Administration. [More]
Researchers reveal that drug-food interactions may endanger mountaineer’s health

Researchers reveal that drug-food interactions may endanger mountaineer’s health

University of the Basque Country researchers have studied the nutritional and health situations existing at high altitudes as well as the routinely used nutritional ergogenic and pharmacological aids. According to their study, the possible interactions between drugs and food and nutrients taken may endanger the mountaineer’s health if all this is not conducted under strict control. [More]
Research performed in anemic mice shows acetate stimulates the formation of red blood cells

Research performed in anemic mice shows acetate stimulates the formation of red blood cells

UT Southwestern Medical Center researchers seeking novel treatments for anemia found that giving acetate, the major component of household vinegar, to anemic mice stimulated the formation of new red blood cells. [More]
Ramucirumab Phase III study meets primary endpoint in patients with metastatic colorectal cancer

Ramucirumab Phase III study meets primary endpoint in patients with metastatic colorectal cancer

Eli Lilly and Company today announced that the RAISE trial, a Phase III study of ramucirumab (CYRAMZA) in combination with chemotherapy in patients with metastatic colorectal cancer (mCRC), met its primary endpoint of overall survival. [More]
UT Southwestern faculty awarded CPRIT grants to combat cancer

UT Southwestern faculty awarded CPRIT grants to combat cancer

UT Southwestern Medical Center faculty have received 19 grants totaling more than $26 million from the Cancer Prevention and Research Institute of Texas to expand cancer screenings, investigate the effectiveness and viability for cancer therapies and radiation treatments, conduct research into cancer biology, and recruitment. [More]
A personalized approach for patients with ccRCC-related mutations

A personalized approach for patients with ccRCC-related mutations

In an analysis of small molecules called metabolites used by the body to make fuel in normal and cancerous cells in human kidney tissue, a research team from the Perelman School of Medicine at the University of Pennsylvania identified an enzyme key to applying the brakes on tumor growth. [More]